Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension
| العنوان: | Combination antihypertensive therapy with valsartan and hydrochlorothiazide in Chinese patients with mild-to-moderate hypertension |
|---|---|
| المؤلفون: | Ning-L, Sun, Jun-R, Zhu, Yanxing, Zhao, Ying-M, Tu, Qi, Bi |
| المصدر: | Current Medical Research and Opinion. 24:2863-2871 |
| بيانات النشر: | Informa Healthcare, 2008. |
| سنة النشر: | 2008 |
| مصطلحات موضوعية: | Adult, Male, China, medicine.medical_specialty, Time Factors, Combination therapy, Tetrazoles, Sitting diastolic blood pressure, Blood Pressure, Essential hypertension, Hydrochlorothiazide, Asian People, Double-Blind Method, Internal medicine, medicine, Humans, Antihypertensive Agents, Aged, Aged, 80 and over, Chinese population, business.industry, Outcome measures, Valine, Sitting systolic blood pressure, General Medicine, Middle Aged, medicine.disease, Valsartan, Hypertension, Physical therapy, Drug Therapy, Combination, Female, business, medicine.drug |
| الوصف: | To compare the efficacy and safety of valsartan (VAL)/HCTZ 80/12.5 mg with VAL 80 mg in Chinese patients with mild-to-moderate essential hypertension not adequately controlled with VAL 80 mg alone.This was a multicenter, double-blind, double-dummy, randomized, active-controlled, parallel-group trial. Patients (1175) with mild-to-moderate essential hypertension (mean sitting diastolic blood pressure [MSDBP]or = 95 and110 mmHg) from 26 centers in China received VAL 80 mg o.d. for 4 weeks, 864 patients whose MSDBP remainedor = 90 and110 mmHg were randomized (1:1) to receive VAL80/HCTZ12.5 mg (n = 429) or VAL80 mg (n = 435) for 8 weeks.The efficacy variable was changed from baseline to endpoint in trough MSDBP. The secondary efficacy variables were changed in mean sitting systolic blood pressure (MSSBP), response rate, and control rate.Significant reductions in MSDBP and MSSBP from baseline to endpoint were observed in both groups. There were significantly greater reductions in MSDBP (8.4 mmHg vs. 6.2 mmHg) and MSSBP (10.2 mmHg vs. 6.7 mmHg), higher response (64.2% vs. 52.5%) and control rates (53.9% vs. 40.9%) in the VAL80/HCTZ12.5 group as compared with the VAL80 group at endpoint (p0.001). VAL80/HCTZ12.5 was equally effective in both age subgroups (or = 65 and65 years) and was well tolerated. There were no deaths and the two serious adverse events reported were unrelated to study medication.In Chinese patients with mild-to-moderate essential hypertension not adequately controlled by VAL 80 mg alone, VAL80/HCTZ12.5 mg combination was well tolerated and showed additional BP reduction. The limitations of this study were the inability to include an HCTZ arm as a control group and the short trial duration. |
| تدمد: | 1473-4877 0300-7995 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cf4b0d032bb67f51269d9887fe61617Test https://doi.org/10.1185/03007990802390647Test |
| رقم الانضمام: | edsair.doi.dedup.....2cf4b0d032bb67f51269d9887fe61617 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14734877 03007995 |
|---|